A Long-Term Follow-Up Basket Study for Participants Treated With SynKIR Chimeric Antigen Receptor (CAR) T Cell Product
Launched by VERISMO THERAPEUTICS · Nov 20, 2024
Trial Information
Current as of August 22, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This is a study for the Long Term Follow Up for all participants treated with Verismo Therapeutics' SynKIR CAR T cell products in accordance with regulatory guidance. The primary objective of this study is to monitor the long-term safety of SynKIR CAR T cell products.
No investigational product will be administered in this LTFU study. Eligible participants must have received at least 1 infusion of a SynKIR CAR T cell product under a Verismo Therapeutics parent protocol. Participants will be invited to enroll into this LTFU study after either early discontinuation from or completion of the ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Participants are eligible to be included in the study only if all of the following criteria apply:
- • 1. All adult participants who have received any amount of SynKIR CAR T cell product in a study sponsored by Verismo Therapeutics.
- • 2. Participant is willing and able to comply with the study requirements.
- Exclusion Criteria:
- • There are no specific exclusion criteria.
About Verismo Therapeutics
Verismo Therapeutics is a biopharmaceutical company dedicated to advancing innovative therapies for the treatment of cancer and other serious diseases. With a focus on harnessing the power of the immune system, Verismo is committed to developing groundbreaking immunotherapies that target specific cellular pathways to enhance patient outcomes. The company’s robust pipeline is supported by cutting-edge research and a team of experienced professionals, ensuring a strong foundation for clinical advancements. Through collaboration and scientific rigor, Verismo Therapeutics aims to transform the landscape of oncology and improve the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Madison, Wisconsin, United States
Westwood, Kansas, United States
Philadelphia, Pennsylvania, United States
Denver, Colorado, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported